Hemophagocytic Lymphohistiocytosis Market

• High-Dose Corticosteroids: Dexamethasone remains a foundational component of HLH treatment, providing potent anti-inflammatory effects and suppression of cytokine-mediated tissue injury.
• Etoposide-Based Regimens: Continue to serve as a cornerstone of first-line therapy, effectively eradicating the excessively activated cytotoxic lymphocytes and macrophages driving disease pathology.
• Immunosuppressive Agents: Cyclosporine is commonly employed to suppress T-cell activation and reduce cytokine release, dampening immune overactivation.
• Targeted Biologic Therapies: Rituximab for EBV-associated HLH, along with monoclonal antibodies such as alemtuzumab or antithymocyte globulin in refractory disease, enable more selective immune modulation.
• Antimicrobial Therapy: When infections serve as triggering factors, concurrent antiviral and antibiotic therapy is critical to address both the precipitating cause and the downstream inflammatory cascade.
• Hematopoietic Stem Cell Transplantation (HSCT): These approaches collectively aim to achieve disease stabilization, enabling eligible patients to proceed to definitive curative options.

GAMIFANT Commercial Performance

GAMIFANT demonstrated robust commercial momentum in Q3 2025, generating USD 66.6 million in revenue—a remarkable 98% year-over-year increase. This growth was propelled by rising patient adoption, favorable product mix, and the successful US launch for macrophage activation syndrome (MAS) in Still's disease, establishing GAMIFANT as the first approved therapy for both pediatric and adult patients in this indication.

This commercial milestone highlights GAMIFANT's broader therapeutic applicability across the HLH–MAS disease spectrum and reinforces its long-term growth trajectory. Looking ahead, GAMIFANT revenues are projected to grow at a low double-digit CAGR at constant exchange rates, supported by global market expansion, enhanced patient access, and sustained uptake across both MAS and HLH indications.

Hemophagocytic Lymphohistiocytosis Competitive Landscape

The HLH pipeline remains notably sparse, with only a handful of emerging therapies: plonmarlimab (TJ Biopharma), ELA026 (Electra Therapeutics), MAS825 (Novartis), and tadekinig alfa (r-hIL-18BP) (AB2 Bio). Despite all being in late-stage development, this limited pipeline underscores the significant scarcity of therapeutic innovation in this space.

Tadekinig Alfa (r-hIL-18BP) – AB2 Bio

AB2 Bio's tadekinig alfa is an innovative recombinant human IL-18 binding protein (IL-18BP) that neutralizes IL-18, a key pro-inflammatory cytokine. Under normal physiological conditions, endogenous IL-18BP is present in excess, maintaining circulating free IL-18 at undetectable levels. In certain autoinflammatory disorders, this regulatory balance is disrupted, leading to elevated systemic free IL-18 and severe pathological hyperinflammation. Tadekinig alfa re-establishes this balance by sequestering excess free IL-18, thereby attenuating inflammatory responses. This mechanism represents a novel and promising therapeutic strategy for autoimmune and inflammatory diseases characterized by elevated systemic IL-18 levels. The therapy is currently being evaluated in a Phase III clinical trial.

ELA026 – Electra Therapeutics

Electra Therapeutics' ELA026 is a monoclonal antibody developed to treat severe inflammatory diseases driven by dysregulated myeloid cells and T-lymphocytes. It selectively and rapidly depletes circulating inflammatory myeloid cells and T cells responsible for disease pathology while preserving the CD47/SIRPα immune checkpoint pathway. ELA026 is presently in Phase II/III clinical development.

MAS825 – Novartis

Novartis is advancing MAS825 through clinical development as a targeted therapeutic candidate for HLH, contributing to the expanding portfolio of emerging treatments in this underserved disease space.